Skip to main content

PTC Therapeutics, Inc.

corporate_fare Company Profile

PTC Therapeutics, Inc.

PTCT·NASDAQ·Life Sciences·CIK 0001070081

PTC THERAPEUTICS, INC. is a global biopharmaceutical company focused on discovering, developing, and selling specialized medicines for children and adults with rare disorders. The company aims to provide access to treatments for patients with unmet medical needs by using its scientific knowledge and global sales network. PTC THERAPEUTICS has a diverse range of therapeutic products, including several that are already on the market and others in various stages of development, from early discovery to clinical trials. These efforts are concentrated on creating new treatments for rare neurological and metabolic diseases. As of the report date, the company's significant commercial products and clinical-stage programs include: Sephience (sepiapterin): This product treats adult and pediatric patients with phenylketonuria (PKU), a rare inherited metabolic disease. PKU prevents the body from breaking down phenylalanine (Phe), which can lead to neurological issues. Sephience works through a dual mechanism to reduce blood Phe levels and can potentially treat a wide range of PKU patients. Sephience is approved in the United States, the European Economic Area (EEA), Japan, and other regions. Global DMD Franchise: This franchise includes two products for Duchenne muscular dystrophy (DMD), a rare and life-threatening disorder: Translarna (ataluren) and Emflaza (deflazacort). Translarna previously held conditional approval in the EEA. However, in March 2025, the European Commission (EC) adopted a negative opinion from the Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), leading to the non-renewal of Translarna's conditional marketing authorization for treating nonsense mutation Duchenne muscular dystrophy (nmDMD).

PTC Therapeutics, Inc. (NASDAQ:PTCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for PTCT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • PTC Therapeutics Reports Positive 24-Month Votoplam Data for Huntington's, Novartis Initiates Phase 3
  • PTC Therapeutics Appoints Biotech Banking Veteran Jessica Chutter to Board
  • PTC Therapeutics Reports Strong 2025 Financials, Driven by $1.0B Novartis Deal and New Product Launches
  • PTC Therapeutics Reports Strong FY2025 Results, Exceeds Revenue Guidance, and Provides Positive 2026 Outlook
  • PTC Therapeutics Withdraws Translarna NDA for Duchenne Muscular Dystrophy Following Negative FDA Feedback

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.73B
Net Income
$682.64M
Diluted EPS
$7.78
Op. Cash Flow
$711.2M
Free Cash Flow
$702.34M
Operating Income
$866.93M
Cash & Equivalents
$984.65M
Debt / Equity
0.00×
Net Margin
39.4%
Shares Outstanding
81.47M sh
Source: 10-K · filed 2026-02-19 · accession 0001104659-26-017575
$56.99 +1.01% today
52-week range · as of 2026-10-29 $56.99 – $90.87
Market cap
$4.71B
Volume
952.6K (0.9× avg)
3-mo avg 1M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PTCT - Filings & News (Page 2)

PTCT
Apr 28, 2026, 4:29 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $72.20
Real-time Price: $56.99 info
Change: -$15.21 (-21%) info
Market Cap: $4.714B info
PTCT
Mar 25, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.73
Real-time Price: $56.99 info
Change: -$7.74 (-12%) info
Market Cap: $4.714B info
PTCT
Feb 19, 2026, 4:36 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $68.00
Real-time Price: $56.99 info
Change: -$11.01 (-16%) info
Market Cap: $4.714B info
PTCT
Feb 19, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $68.00
Real-time Price: $56.99 info
Change: -$11.01 (-16%) info
Market Cap: $4.714B info
PTCT
Feb 12, 2026, 5:10 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $69.00
Real-time Price: $56.99 info
Change: -$12.01 (-17%) info
Market Cap: $4.714B info
PTCT
Jan 12, 2026, 12:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $76.07
Real-time Price: $56.99 info
Change: -$19.07 (-25%) info
Market Cap: $4.714B info
PTCT
Jan 06, 2026, 4:24 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $78.44
Real-time Price: $56.99 info
Change: -$21.45 (-27%) info
Market Cap: $4.714B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets